Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$1.08
-12.2%
$1.28
$0.86
$3.78
$269.04M0.353.85 million shs19.09 million shs
Altimmune, Inc. stock logo
ALT
Altimmune
$3.61
-2.2%
$5.14
$2.90
$11.16
$299.29M-0.013.61 million shs1.80 million shs
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.47
-4.7%
$3.41
$2.45
$4.14
$311.51M0.25376,402 shs313,746 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.88
$1.76
$1.40
$7.88
$83.45M1.55476,027 shs153,036 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-12.20%-28.00%-10.00%-36.47%-63.27%
Altimmune, Inc. stock logo
ALT
Altimmune
-2.17%-11.52%-26.33%-37.44%-43.24%
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-4.67%-11.03%-4.41%+16.44%-9.16%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00%0.00%+10.59%+8.67%-64.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.9872 of 5 stars
4.52.00.00.00.82.50.6
Altimmune, Inc. stock logo
ALT
Altimmune
2.2452 of 5 stars
3.43.00.00.01.31.70.6
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
1.692 of 5 stars
3.30.00.00.00.62.51.3
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.1884 of 5 stars
1.05.00.00.00.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.90
Moderate Buy$8.44681.89% Upside
Altimmune, Inc. stock logo
ALT
Altimmune
2.75
Moderate Buy$18.20404.16% Upside
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.50
Moderate Buy$6.0072.91% Upside
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.006.38% Upside

Current Analyst Ratings Breakdown

Latest EPIX, AVIR, ALT, and ALLO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Altimmune, Inc. stock logo
ALT
Altimmune
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
7/10/2025
Altimmune, Inc. stock logo
ALT
Altimmune
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.00
6/27/2025
Altimmune, Inc. stock logo
ALT
Altimmune
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
6/27/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
5/15/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $4.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$20K11,811.42N/AN/A$2.01 per share0.54
Altimmune, Inc. stock logo
ALT
Altimmune
$20K14,640.36N/AN/A$1.74 per share2.07
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$5.20 per shareN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)
Altimmune, Inc. stock logo
ALT
Altimmune
-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/7/2025 (Estimated)
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)

Latest EPIX, AVIR, ALT, and ALLO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.3006N/AN/AN/A$0.00 millionN/A
8/7/2025Q2 2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.44N/AN/AN/AN/AN/A
8/6/2025N/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28N/AN/AN/AN/AN/A
8/4/2025Q3 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.2430N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28-$0.28N/A-$0.28$0.00 millionN/A
5/13/2025Q1 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million
5/12/2025Q1 2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.56-$0.40+$0.16-$0.40N/AN/A
5/8/2025Q2 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.19-$0.14+$0.05-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
9.71
9.71
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
15.85
15.85
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
19.94
19.94
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
67.15
67.15

Institutional Ownership

CompanyInstitutional Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%

Insider Ownership

CompanyInsider Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
13.20%
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
18.10%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
310218.73 million189.86 millionOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5081.11 million77.78 millionOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7085.58 million70.09 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.39 million37.51 millionOptionable

Recent News About These Companies

ESSA Pharma (EPIX) Expected to Announce Earnings on Monday
ESSA Pharma to be Acquired by XenoTherapeutics

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Allogene Therapeutics stock logo

Allogene Therapeutics NASDAQ:ALLO

$1.08 -0.15 (-12.20%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.08 -0.01 (-0.46%)
As of 08/1/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Altimmune stock logo

Altimmune NASDAQ:ALT

$3.61 -0.08 (-2.17%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.64 +0.04 (+0.97%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$3.47 -0.17 (-4.67%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.48 +0.00 (+0.14%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$1.88 0.00 (0.00%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.88 0.00 (0.00%)
As of 08/1/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.